Timothy H Holtz1,2, Anupong Chitwarakorn3, James P Hughes4,5, Marcel E Curlin1,2,6, Anchalee Varangrat1, Maoji Li5, K Rivet Amico7, Philip A Mock1, Robert M Grant8. 1. Thailand Ministry of Public Health-U.S., Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand. 2. Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA. 3. Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand. 4. Department of Biostatistics, University of Washington, Seattle, WA. 5. Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA. 6. Department of Medicine, Oregon Health Sciences University, Portland, OR. 7. Department of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, MI. 8. Department of Medicine, University of California, San Francisco, CA.
Abstract
BACKGROUND: We identified correlates of sex-related pre-exposure prophylaxis (PrEP) adherence in HPTN067/ADAPT, a phase 2, open-label feasibility study of daily and nondaily regimens of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)-based PrEP, among Thai men who have sex with men (MSM), and transgender women (TGW), Bangkok. METHODS: Participants were randomly assigned to one of three self-administered dosing regimens for 24 weeks: daily, time-driven, or event-driven. Demographic and behavioral information was obtained at screening. Pill-container opening was recorded with electronic dose monitoring, and self-reported information on PrEP use, sex events, and substance use was obtained during weekly interviews to confirm dose data. Sex-related PrEP adherence was calculated as the proportion of sex events covered by PrEP use (at least one tablet taken within 4 days before sex and at least one tablet taken within 24 hours after sex) to total sex events. We used multivariate modeling with sex event as the unit of analysis to evaluate correlates associated with sex-related PrEP adherence. RESULTS: Among 178 MSM and TGW, sex-related PrEP adherence was similar in the daily and time-driven arms (P = 0.79), both significantly greater than the event-driven arm (P = 0.02 compared to daily). Sex-related PrEP adherence by those reporting stimulant use (74.2%) was similar to those reporting other nonalcohol drug use (76.3%, P = 0.80), but lower than those reporting no substance use (84.6%, P = 0.04). In a multivariable model, randomization to the event-driven arm, a higher prestudy number of reported sex events, and use of stimulant drugs were associated with significantly lower sex-related PrEP adherence. CONCLUSION: Adherence was influenced by treatment schedule and adversely affected by nonalcoholic substance use. Regardless of these factors, Thai MSM and TGW maintained high adherence levels to oral PrEP dosing regimens and coverage of sexual exposures.
BACKGROUND: We identified correlates of sex-related pre-exposure prophylaxis (PrEP) adherence in HPTN067/ADAPT, a phase 2, open-label feasibility study of daily and nondaily regimens of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)-based PrEP, among Thai men who have sex with men (MSM), and transgender women (TGW), Bangkok. METHODS: Participants were randomly assigned to one of three self-administered dosing regimens for 24 weeks: daily, time-driven, or event-driven. Demographic and behavioral information was obtained at screening. Pill-container opening was recorded with electronic dose monitoring, and self-reported information on PrEP use, sex events, and substance use was obtained during weekly interviews to confirm dose data. Sex-related PrEP adherence was calculated as the proportion of sex events covered by PrEP use (at least one tablet taken within 4 days before sex and at least one tablet taken within 24 hours after sex) to total sex events. We used multivariate modeling with sex event as the unit of analysis to evaluate correlates associated with sex-related PrEP adherence. RESULTS: Among 178 MSM and TGW, sex-related PrEP adherence was similar in the daily and time-driven arms (P = 0.79), both significantly greater than the event-driven arm (P = 0.02 compared to daily). Sex-related PrEP adherence by those reporting stimulant use (74.2%) was similar to those reporting other nonalcohol drug use (76.3%, P = 0.80), but lower than those reporting no substance use (84.6%, P = 0.04). In a multivariable model, randomization to the event-driven arm, a higher prestudy number of reported sex events, and use of stimulant drugs were associated with significantly lower sex-related PrEP adherence. CONCLUSION: Adherence was influenced by treatment schedule and adversely affected by nonalcoholic substance use. Regardless of these factors, Thai MSM and TGW maintained high adherence levels to oral PrEP dosing regimens and coverage of sexual exposures.
Authors: Julia H Arnsten; Penelope A Demas; Richard W Grant; Marc N Gourevitch; Homayoon Farzadegan; Andrea A Howard; Ellie E Schoenbaum Journal: J Gen Intern Med Date: 2002-05 Impact factor: 5.128
Authors: Beryl A Koblin; Margaret A Chesney; Marla J Husnik; Sam Bozeman; Connie L Celum; Susan Buchbinder; Kenneth Mayer; David McKirnan; Franklyn N Judson; Yijian Huang; Thomas J Coates Journal: Am J Public Health Date: 2003-06 Impact factor: 9.308
Authors: Michael W Plankey; David G Ostrow; Ron Stall; Christopher Cox; Xiuhong Li; James A Peck; Lisa P Jacobson Journal: J Acquir Immune Defic Syndr Date: 2007-05-01 Impact factor: 3.731
Authors: R Stall; J P Paul; G Greenwood; L M Pollack; E Bein; G M Crosby; T C Mills; D Binson; T J Coates; J A Catania Journal: Addiction Date: 2001-11 Impact factor: 6.526
Authors: Charles H Hinkin; David J Hardy; Karen I Mason; Steven A Castellon; Ramani S Durvasula; Mona N Lam; Marta Stefaniak Journal: AIDS Date: 2004-01-01 Impact factor: 4.177
Authors: Beryl A Koblin; Marla J Husnik; Grant Colfax; Yijian Huang; Maria Madison; Kenneth Mayer; Patrick J Barresi; Thomas J Coates; Margaret A Chesney; Susan Buchbinder Journal: AIDS Date: 2006-03-21 Impact factor: 4.177
Authors: Peter A Vanable; David J McKirnan; Susan P Buchbinder; Bradford N Bartholow; John M Douglas; Franklyn N Judson; Kathleen M MacQueen Journal: Health Psychol Date: 2004-09 Impact factor: 4.267
Authors: Michael Viamonte; Delaram Ghanooni; John M Reynolds; Christian Grov; Adam W Carrico Journal: Curr HIV/AIDS Rep Date: 2022-06-14 Impact factor: 5.495
Authors: Paul A Shuper; Narges Joharchi; Isaac I Bogoch; Mona Loutfy; Frederic Crouzat; Philippe El-Helou; David C Knox; Kevin Woodward; Jürgen Rehm Journal: BMC Public Health Date: 2020-11-25 Impact factor: 3.295
Authors: Paul A Shuper; Thepikaa Varatharajan; David J Kinitz; Dionne Gesink; Narges Joharchi; Isaac I Bogoch; Mona Loutfy; Jürgen Rehm Journal: BMC Public Health Date: 2022-10-07 Impact factor: 4.135